Type: Breast cancer
Dr Michelle McDonald and her team are in a unique position to examine how some drugs help to keep cancer cells in bone at bay.
This project has worked to improve treatments and reduce the major challenge of some breast cancer patients’ resistance to endocrine therapy and relapse.
Professor Clarke’s team has been unravelling the complexities of breast cancer by providing new insight into the structure of the normal breast and how progesterone may be linked with cancer risk.
This project will lay the foundations for possible clinical trials of drugs targeting the ELF5 protein as a way of preventing hormone therapy resistance in breast cancer.
Resistance to endocrine therapies is common, affecting around 40% of people who undergo treatment for breast cancer. Dr Caldon’s team investigated the underlying causes of this resistance.
If the project is successful, it would be one of the first targeted treatments for triple-negative breast cancer, with potential for improved survival rates.
This project is a critical step to expand treatment options and could also pave the way for development of immune therapies for breast cancer.
Professor Robert Baxter and his team have tested a promising new therapy, which can effectively block the growth of triple negative breast cancer by inhibiting two proteins that act as stimulators.
Shirley Baxter talks about representing consumers in deciding what research Cancer Council funds.
A team of researchers led by Dr Nicole Verrills has been investigating if a new ‘gene marker’ can predict which breast cancer patients may have poorer treatment outcomes.